SKBR3

SkBr3 is a cell line isolated by the Memorial Sloan–Kettering Cancer Center in 1970. It was derived from a pleural effusion due to an adenocarcinoma originating in the breast of a 43-year-old, caucasian female. The cell line over-expresses the HER2 gene product. [1]

The SkBr3 line is synonymous(derived from the same patient) with the AU565 cell line.[2]

The SkBr3 cell line has been used in studies seeking to overcome Herceptin resistance to HER2-overexpressing breast cancer.[3]

The cells are considered biosafety level 1.[1]

References

  1. 1 2 "ATCC Product Description". Retrieved 26 February 2012.
  2. ↑ "LBL Breast Cancer Cell Collection: Cell Line AU565". Retrieved 26 February 2012.
  3. ↑ "Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor". Retrieved 26 February 2012.

External links

This article is issued from Wikipedia - version of the 2/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.